Influenza Virus Vaccine Adjuvanted Pandemic H1N1 (2009) the Young Children following Two Doses of Unusual Patterns of IgG Avidity in Some

[1]  M. Paunio,et al.  Waning antibody levels and avidity: implications for MMR vaccine-induced protection. , 2012, The Journal of infectious diseases.

[2]  D. M. Pérez-Filgueira,et al.  Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against Foot-and-Mouth Disease Virus in cattle. , 2012, Vaccine.

[3]  R. Jefferis.  Isotype and glycoform selection for antibody therapeutics. , 2012, Archives of biochemistry and biophysics.

[4]  R. Karron,et al.  Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. , 2012, The Journal of infectious diseases.

[5]  D. Skowronski,et al.  Influenza B/Victoria Antigen Induces Strong Recall of B/Yamagata But Lower B/Victoria Response in Children Primed With Two Doses of B/Yamagata , 2011, The Pediatric infectious disease journal.

[6]  H. Prince,et al.  Utility of IgM/IgG Ratio and IgG Avidity for Distinguishing Primary and Secondary Dengue Virus Infections Using Sera Collected More than 30 Days after Disease Onset , 2011, Clinical and Vaccine Immunology.

[7]  J. Yewdell,et al.  MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines , 2011, Science Translational Medicine.

[8]  O. Vanderkooi,et al.  Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children , 2011, The Pediatric infectious disease journal.

[9]  P. Chomez,et al.  Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. , 2011, Vaccine.

[10]  G. Leroux-Roels,et al.  H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses , 2010, Journal of Clinical Immunology.

[11]  D. Griffin,et al.  Comparison of the Immune Responses Induced by Chimeric Alphavirus-Vectored and Formalin-Inactivated Alum-Precipitated Measles Vaccines in Mice , 2010, PloS one.

[12]  James E. Crowe,et al.  Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus , 2010, Science.

[13]  M. Permezel,et al.  Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  G. Leroux-Roels,et al.  An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. , 2008, The Journal of infectious diseases.

[15]  G. Leroux-Roels,et al.  Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine , 2008, PloS one.

[16]  D. Griffin,et al.  Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. , 2007, The Journal of infectious diseases.

[17]  G. Leroux-Roels,et al.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial , 2007, The Lancet.

[18]  A. Atrasheuskaya,et al.  Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. , 2006, Vaccine.

[19]  M. Busch,et al.  Immunoglobulin G Avidity in Differentiation between Early and Late Antibody Responses to West Nile Virus , 2006, Clinical and Vaccine Immunology.

[20]  H. Soleimanjahi,et al.  Assessment of IgM enzyme immunoassay and IgG avidity assay for distinguishing between primary and secondary immune response to rubella vaccine. , 2005, Journal of virological methods.

[21]  R. Cox,et al.  The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. , 1999, The Journal of infectious diseases.

[22]  L. Hanson,et al.  Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content , 1993, Acta paediatrica.

[23]  R. Feldman,et al.  IgG subclass distribution of antibodies to bacterial and viral antigens , 1990, The Pediatric infectious disease journal.

[24]  J. Mackenzie,et al.  Serum IgG subclass responses of humans to inactivated and live influenza A vaccines compared to natural infections with influenza A , 1990, Journal of medical virology.

[25]  K. Hedman,et al.  Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (Avidity‐ELISA) and by haemolysis typing , 1989, Journal of medical virology.

[26]  J. Davies,et al.  Infection with influenza A H1N1: 1. Production and persistence of antibody , 1986, Journal of Hygiene.

[27]  B. Marshall,et al.  Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). , 2003, Viral immunology.

[28]  C. Mohan,et al.  The Human IgG Subclasses , 2001 .

[29]  D. Knook,et al.  Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. , 1999, The Journal of infectious diseases.

[30]  G. Schild,et al.  The use of transportable single-radial-diffusion immunoplates in seroepidemiological studies of influenza in the Gambia. The occurrence and persistence of antibody to influenza A/Hong Kong/68 (H3N2) virus in selected inhabitants of two rural villages. , 1977, Bulletin of the World Health Organization.